GELS
$0.79
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia.
Intraday
Recent News
Gelteq announces preclinical results on medicinal cannabinoid absorption
Gelteq (GELS) announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol compared to an existing FDA approved oil-based product. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a
Top Midday Gainers
SINTX Technologies (SINT) said Wednesday it published a peer-reviewed study demonstrating that silic